IN DEVELOPMENT: CB003

Cubed's first compound in development: a stacked multiple-API formula

Illustration

Psilocybin | 20 mg

Derived from psilocybe mushrooms

Illustration

Mescaline | 100 mg

Mescaline is derived from cacti:San Pedro, Peyote & Peruvian Toruch

Illustration

DMT/MAO | 5 mg

The two active ingredients in Ayahuasca

Our Path

We will partner with universities to conduct clinical trials then produce our proprietary drug compounds and manufacture for our partners.

TACKLING THE MENTAL HEALTH CRISIS

A Vast Global Potential Market already used for centuries for:

DEPRESSION – ADDICTION - POST-TRAUMATIC STRESS DISORDER (PTSD)Growing psychedelic research & acceptance for treating depression FDA is fast-tracking Psilocybin as a ”Breakthrough Treatment” COVID-19 has increased global mental health awareness
ACTIVE GOVERNMENTAL RESPONSERising Health care costs force governments to look for economic therapiesCannabis legalization opened new regulations, infrastructure & reduces stigmaGovernments leading the charge: U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA) invested $27 million in psychedelicsSource: https://thedalesreport.com/psychedelics/what-the-u-s-militarys-27-million-investment-in-novel-psychedelic-type-drugs-could-mean-for-veterans